(LBRX) LB Pharmaceuticals Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 803m USD | Total Return: 62.5% in 12m
Avg Turnover: 4.39M
Warnings
Share dilution 11115.9% YoY
High Debt/EBITDA (7.8) with thin interest coverage (-225.2)
High Debt while negative Cash Flow
Interest Coverage Ratio -225.2 is critical
Altman Z'' -6.98 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
LB Pharmaceuticals Inc (LBRX) is a clinical-stage biopharmaceutical firm based in New York, specializing in treatments for neuropsychiatric conditions. The company’s primary focus is the development of LB-102, a small molecule oral therapy currently in Phase 3 clinical trials for acute schizophrenia and undergoing evaluation for bipolar I depression and major depressive disorder.
The company operates within the central nervous system (CNS) therapeutic sector, a field characterized by high regulatory hurdles and lengthy clinical trial timelines. Unlike diversified pharmaceutical giants, clinical-stage firms typically operate on a research and development business model, prioritizing pipeline advancement and intellectual property over immediate commercial revenue.
Investors may find it useful to evaluate the companys long-term valuation prospects on ValueRay. Given the risks inherent in Phase 3 trials, monitoring clinical data readouts and capital expenditure remains essential for assessing the viability of the LB-102 platform.
- Phase 3 clinical trial results for LB-102 determine primary valuation
- Regulatory approval of LB-102 creates first commercial revenue stream
- Expansion into bipolar depression and MDD indications increases addressable market
- High research and development expenditures necessitate future capital raises
- Patent protection duration for proprietary oral small molecules impacts long-term value
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA 252.2 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.13 > 3% & CFO -51.6m > Net Income -39.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 35.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.2m) vs 12m ago 11.1k% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -225.2 > 6 (EBITDA TTM -46.2m / Interest Expense TTM 206k) |
| A: 0.96 (Total Current Assets 389.1m - Total Current Liabilities 10.9m) / Total Assets 393.5m |
| B: -0.38 (Retained Earnings -148.6m / Total Assets 393.5m) |
| C: -0.23 (EBIT TTM -46.5m / Avg Total Assets 206.4m) |
| D: -10.03 (Book Value of Equity -148.4m / Total Liabilities 14.8m) |
| Altman-Z'' = -6.98 = D |
As of May 24, 2026, the stock is trading at USD 28.00 with a total of 152,983 shares traded.
Over the past week, the price has changed by -5.19%,
over one month by -11.52%,
over three months by +17.12% and
over the past year by +62.54%.
LB Pharmaceuticals Common has no consensus analysts rating.
Revenue TTM = 0.0 USD
EBIT TTM = -46.5m USD
EBITDA TTM = -46.2m USD
Long Term Debt = 2.74m USD (estimated: total debt 3.47m - short term 730k)
Short Term Debt = 730k USD (from shortTermDebt, last quarter)
Debt = 3.47m USD (from shortLongTermDebtTotal, last quarter) (leases 3.47m already included)
Net Debt = -362.2m USD (calculated: Debt 3.47m - CCE 365.6m)
Enterprise Value = 440.8m USD (802.9m + Debt 3.47m - CCE 365.6m)
Interest Coverage Ratio = -225.2 (Ebit TTM -46.5m / Interest Expense TTM 206k)
EV/FCF = -8.52x (Enterprise Value 440.8m / FCF TTM -51.7m)
FCF Yield = -11.73% (FCF TTM -51.7m / Enterprise Value 440.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 321k) / Revenue TTM)
Tobins Q-Ratio = 1.12 (Enterprise Value 440.8m / Total Assets 393.5m)
Interest Expense / Debt = 5.95% (Interest Expense 206k / Debt 3.47m)
Taxrate = 21.0% (US default 21%)
NOPAT = -36.7m (EBIT -46.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 35.68 (Total Current Assets 389.1m / Total Current Liabilities 10.9m)
Debt / Equity = 0.01 (Debt 3.47m / totalStockholderEquity, last quarter 378.7m)
Debt / EBITDA = 7.84 (negative EBITDA) (Net Debt -362.2m / EBITDA -46.2m)
Debt / FCF = 7.00 (negative FCF - burning cash) (Net Debt -362.2m / FCF TTM -51.7m)
Total Stockholder Equity = 221.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.98% (Net Income -39.2m / Total Assets 393.5m)
RoE = -10.58% (Net Income TTM -39.2m / Total Stockholder Equity 370.2m)
RoCE = -12.47% (EBIT -46.5m / Capital Employed (Equity 370.2m + L.T.Debt 2.74m))
RoIC = -20.32% (negative operating profit) (NOPAT -36.7m / Invested Capital 180.8m)
WACC = 10.63% (E(802.9m)/V(806.4m) * Re(10.66%) + D(3.47m)/V(806.4m) * Rd(5.95%) * (1-Tc(0.21)))
Discount Rate = 10.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 45.73 | Cagr: 182.4%
[DCF] Fair Price = unknown (Cash Flow -51.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.82 | Chg30d=+5.19% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.94 | Chg30d=+6.68% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=-3.50 | Chg30d=+5.48% | Revisions=+20% | GrowthEPS=-11.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.49 | Chg30d=-5.20% | Revisions=+20% | GrowthEPS=-28.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -20%